S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:BMRA

Biomerica (BMRA) Competitors

$1.28
-0.09 (-6.57%)
(As of 06/1/2023 ET)
Compare
Today's Range
$1.28
$1.40
50-Day Range
$1.12
$1.99
52-Week Range
$1.08
$5.25
Volume
27,716 shs
Average Volume
39,292 shs
Market Capitalization
$21.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BMRA vs. OCX, AWH, TRIB, CDIO, ICCC, NYMX, MYMD, VBIV, SNCE, and IMPL

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include OncoCyte (OCX), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), ImmuCell (ICCC), Nymox Pharmaceutical (NYMX), MyMD Pharmaceuticals (MYMD), VBI Vaccines (VBIV), Science 37 (SNCE), and Impel Pharmaceuticals (IMPL). These companies are all part of the "medical" sector.

Biomerica vs.

Biomerica (NASDAQ:BMRA) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.

Biomerica has a beta of -0.62, indicating that its share price is 162% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.

In the previous week, Biomerica and Biomerica both had 1 articles in the media. Biomerica's average media sentiment score of 1.00 beat OncoCyte's score of 0.63 indicating that Biomerica is being referred to more favorably in the media.

Company Overall Sentiment
Biomerica Positive
OncoCyte Positive

Biomerica received 136 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 12.50% of users gave OncoCyte an outperform vote.

CompanyUnderperformOutperform
BiomericaOutperform Votes
137
67.82%
Underperform Votes
65
32.18%
OncoCyteOutperform Votes
1
12.50%
Underperform Votes
7
87.50%

22.0% of Biomerica shares are owned by institutional investors. Comparatively, 81.2% of OncoCyte shares are owned by institutional investors. 15.7% of Biomerica shares are owned by company insiders. Comparatively, 6.7% of OncoCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

OncoCyte has a consensus target price of $1.11, suggesting a potential upside of 388.58%. Given OncoCyte's higher probable upside, analysts plainly believe OncoCyte is more favorable than Biomerica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
OncoCyte
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Biomerica has a net margin of -74.56% compared to OncoCyte's net margin of -787.97%. OncoCyte's return on equity of -34.08% beat Biomerica's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomerica -74.56% -95.15% -70.12%
OncoCyte -787.97% -34.08% -15.49%

Biomerica has higher revenue and earnings than OncoCyte.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomerica$18.87 million1.14-$4.53 million-$0.54-2.37
OncoCyte$875 thousand31.04-$72.90 millionN/AN/A

Summary

Biomerica and OncoCyte tied by winning 7 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$21.52M$2.27B$4.54B$6.20B
Dividend YieldN/A0.80%2.42%6.15%
P/E Ratio-2.3727.00100.6311.94
Price / Sales1.14695.583,636.6695.58
Price / CashN/A4,388.1290.91108.26
Price / Book1.9720.635.157.27
Net Income-$4.53M$27.00M$117.81M$193.48M
7 Day Performance-16.34%-0.32%3.21%2.60%
1 Month Performance-5.19%-0.12%3.14%3.08%
1 Year Performance-64.25%-12.04%23.11%1.73%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCX
OncoCyte
2.4488 of 5 stars
$0.22
+4.7%
$1.11
+400.9%
-80.2%$26.49M$960,000.000.00N/AGap Down
AWH
Aspira Women's Health
1.6541 of 5 stars
$3.29
-6.0%
$30.00
+811.9%
-63.7%$27.41M$8.18M-0.25106Gap Down
TRIB
Trinity Biotech
1.5711 of 5 stars
$0.90
-2.2%
N/A-34.5%$34.30M$74.78M-0.70543Analyst Report
Gap Down
CDIO
Cardio Diagnostics
2.2418 of 5 stars
$1.54
+4.8%
$8.00
+419.5%
N/A$14.94MN/A0.00N/A
ICCC
ImmuCell
0 of 5 stars
$5.06
-5.4%
N/A-41.2%$39.22M$18.57M-7.3360Positive News
Gap Down
NYMX
Nymox Pharmaceutical
0 of 5 stars
$0.45
+9.8%
N/A+5.0%$40.72MN/A-11.253Analyst Report
Gap Up
MYMD
MyMD Pharmaceuticals
0 of 5 stars
$1.83
-15.7%
N/A-42.2%$72.23MN/A-5.086
VBIV
VBI Vaccines
1.8699 of 5 stars
$3.02
+5.2%
$40.00
+1,224.5%
-83.8%$26.00M$1.08M-0.22149
SNCE
Science 37
1.9204 of 5 stars
$0.22
-18.5%
$3.50
+1,487.3%
-93.3%$25.75M$70.15M-0.21601Gap Up
IMPL
Impel Pharmaceuticals
2.2222 of 5 stars
$1.10
-8.3%
$15.00
+1,261.7%
-82.0%$26.16M$12.65M-0.24129Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:BMRA) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -